Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California, with news flow centered on development of its investigational Hemopurifier device. Company announcements highlight progress in oncology and infectious disease programs, capital markets activity, and regulatory interactions that shape the outlook for AEMD stock.
Recent news releases describe Aethlon’s ongoing safety, feasibility, and dose-finding oncology trial in Australia, where the Hemopurifier is being evaluated in patients with solid tumors who have not responded to anti-PD-1 therapies. Updates have covered early observations on extracellular vesicles, microRNAs, and lymphocyte counts in initial cohorts, along with protocol amendments and site activity. The company also reports collaborations in Long COVID research, including preclinical data showing that its GNA affinity resin binds extracellular vesicles in Long COVID plasma and depletes EV-associated microRNAs linked to inflammatory pathways.
Investors following AEMD news will also see regular disclosures on financing transactions, such as public offerings and private placements of common stock, pre-funded warrants, and common stock purchase warrants. These items detail gross proceeds, warrant terms, and intended uses of capital for clinical trials, research and development, and working capital. Additional coverage includes patent issuances related to Long COVID and COVID-19-associated coagulopathy, Nasdaq listing compliance updates, and scheduling of quarterly financial results and conference calls.
This news page aggregates Aethlon Medical’s press releases and related coverage so readers can review clinical updates, scientific publications, financing events, and regulatory milestones in one place. For those tracking AEMD, it offers a structured view of how the company communicates progress on the Hemopurifier and its broader development strategy over time.
Aethlon Medical (Nasdaq: AEMD) announced participation in two key investor conferences in September 2022. The first is the H.C. Wainwright 24th Annual Global Investment Conference from Sept. 12-14, where pre-recorded presentations will be available on-demand from Sept. 12, 7:00 a.m. EDT. The second is the Life Sciences Investor Forum on Sept. 15, featuring a live presentation at 2 p.m. EDT. The presentations will highlight Aethlon's innovative Hemopurifier for treating cancer and infectious diseases, designed to remove harmful components from the bloodstream.
Aethlon Medical (AEMD) reported its financial results for the first quarter ending June 30, 2022, highlighting a cash balance of approximately $14.9 million. The company experienced a 30% increase in operating expenses, totaling around $2.91 million, primarily due to higher general and administrative costs. Revenue dropped from $132,000 in Q1 2021 to zero in the same period of 2022, resulting in a net loss of approximately $2.9 million. Aethlon is advancing clinical trials for its Hemopurifier® device targeting COVID-19 and cancer, and plans to assess its effectiveness against the monkeypox virus.
Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for the first quarter ending June 30, 2022, on August 9, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss the results and recent corporate developments. Interested parties can register for the call or dial in. The Hemopurifier, Aethlon's main product, has FDA Breakthrough Device designation for treating cancer and infectious diseases, showing promise in reducing harmful exosomes and viruses from blood, including SARS-CoV-2.
Aethlon Medical (AEMD) announced a peer-reviewed article published in PLOS ONE, showcasing that its GNA affinity resin in the Hemopurifier effectively captures seven SARS-CoV-2 variants, with efficacy ranging from 53% to 89%. CEO Charles J. Fisher emphasized the potential of the Hemopurifier in addressing emerging COVID-19 variants. The company is currently conducting an Early Feasibility Study involving 40 severe COVID-19 patients, and recently received FDA protocol amendment approval to eliminate prior dialysis treatment, which may expedite patient enrollment.
Aethlon Medical (AEMD) announced FDA approval for a protocol amendment in its ongoing clinical trial for the Aethlon Hemopurifier® targeting severe COVID-19 patients. The amendment removes the requirement for patients to have a dialysis catheter, potentially accelerating patient enrollment. The Hemopurifier is designed to filter out life-threatening viruses and harmful exosomes from blood and is being evaluated in a feasibility study involving up to 40 patients across multiple clinical sites. The company aims to enhance patient access to this innovative therapy.
Aethlon Medical (Nasdaq: AEMD) reported financials for the fiscal year ended March 31, 2022, revealing a cash balance of $17.1 million and a revenue of approximately $294,000, a decline from $659,000 in the prior year. Operating expenses rose to $10.72 million from $8.55 million, leading to a net loss of $10.4 million. The company is advancing the Hemopurifier for COVID-19 treatment and cancer, enrolling patients across multiple sites. Recent developments include ethics approval for a clinical trial in India and the appointment of Angela Rossetti to the Board.
Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for the fiscal year ending March 31, 2022, on June 28, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss these results and recent corporate developments. The Hemopurifier, Aethlon's lead technology, is designed to treat cancer and infectious diseases, holding FDA Breakthrough Device designation for advanced cancer therapy and addressing life-threatening viruses. A replay of the conference will be available for a month post-call.
Summary not available.
Aethlon Medical, Inc. (AEMD), a medical technology company, will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami Beach, Florida, and virtually. The presentation, led by CEO Charles J. Fisher, Jr., CMO Steven LaRosa, and CFO James Frakes, will cover updates on the Hemopurifier®, a device aimed at treating cancer and viral infections. The presentation will be available on-demand starting May 24, 2022, at 7 a.m. EDT. The Hemopurifier® has received FDA designations as a Breakthrough Device for cancer and life-threatening viral infections, including COVID-19.
Aethlon Medical announced the publication of a pre-print manuscript showing its GNA affinity resin can capture seven SARS-CoV-2 variants, including Delta and Omicron, with efficiency rates between 53% and 89%. This resin is part of the Aethlon Hemopurifier®, an investigational device designed to remove viruses from the blood. The company is conducting an Early Feasibility Study on the Hemopurifier for COVID-19 patients. This research supports the potential effectiveness of the Hemopurifier against future variants, as stated by CEO Charles J. Fisher, Jr.